本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

BioCryst製藥

7.32
+0.07000.97%
盤後7.350.0310+0.42%19:10 EDT
成交量:572.91萬
成交額:4,211.24萬
市值:15.41億
市盈率:-41.08
高:7.47
開:7.28
低:7.18
收:7.25
52周最高:11.31
52周最低:6.00
股本:2.11億
流通股本:2.08億
量比:1.19
換手率:2.76%
股息:- -
股息率:- -
每股收益(TTM):-0.1782
每股收益(LYR):-0.4300
淨資產收益率:587.33%
總資產收益率:7.46%
市淨率:-3.66
市盈率(LYR):-17.02

資料載入中...

公司資料

公司名字:
BioCryst製藥
交易所:
NASDAQ
成立時間:
1986
員工人數:
580
公司地址:
4505 Emperor Boulevard,Suite 200,Durham,North Carolina,United States
郵編:
27703
電話:
傳真:
919 859 1314
簡介:
BioCryst Pharmaceuticals, Inc.是一家特拉華州公司,最初成立於1986年。該公司是一家全球性生物技術公司,致力於改善遺傳性血管性水腫和罕見病患者的生活。該公司利用結構引導藥物設計方面的專業知識,目標是開發一流或一流的口服小分子和注射蛋白療法,以針對難以治療的罕見疾病。

董事

名稱
職位
Charles K. Gayer
Director and Chief Executive Officer, President
Nancy J. Hutson
Chairman of the Board
A. Machelle Sanders
Independent Director
Alan G. Levin
Independent Director
Amy E. McKee
Independent Director
Steven K. Galson
Independent Director
Theresa M. Heggie
Independent Director
Vincent J. Milano
Independent Director
Jon P. Stonehouse
Director
Steven Frank
Director

股東

名稱
職位
Charles K. Gayer
Director and Chief Executive Officer, President
Babar Ghias
Chief Financial Officer,Principal Accounting Officer and Head of Corporate Development
Helen M. Thackray
Chief Research and Development Officer